---
title: "EBS.US (EBS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EBS.US/news.md"
symbol: "EBS.US"
name: "EBS.US"
parent: "https://longbridge.com/en/quote/EBS.US.md"
datetime: "2026-05-20T00:36:20.861Z"
locales:
  - [en](https://longbridge.com/en/quote/EBS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EBS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EBS.US/news.md)
---

# EBS.US (EBS.US) — Related News

### [Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] | EBS Stock News](https://longbridge.com/en/news/286775728.md)
*2026-05-18T04:59:00.000Z*
> Emergent BioSolutions has received approval from the Saudi Food and Drug Authority for ACAM2000®, a vaccine for smallpox

### [Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved](https://longbridge.com/en/news/284970634.md)
*2026-05-02T14:29:55.000Z*
> Emergent BioSolutions held its 2026 Annual Meeting, where shareholders approved all proposals, including director electi

### [Emergent BioSolutions Earnings Call Highlights Turnaround Momentum](https://longbridge.com/en/news/284949822.md)
*2026-05-02T00:45:39.000Z*
> Emergent BioSolutions (EBS) reported a cautiously optimistic Q1 earnings call, highlighting progress in its turnaround p

### [Riot Platforms Q1 2026 Earnings Call: Complete Transcript](https://longbridge.com/en/news/284842813.md)
*2026-04-30T21:50:21.000Z*
> Riot Platforms (NASDAQ:RIOT) reported an EBITDA loss of $311 million in Q1 2026, primarily due to non-cash accounting ad

### [12 Health Care Stocks Moving In Thursday's After-Market Session](https://longbridge.com/en/news/284837470.md)
*2026-04-30T21:06:05.000Z*
> In Thursday's after-market session, Cue Biopharma (CUE) shares surged 45.1% to $21.5, while Shuttle Pharmaceuticals (SHP

### [](https://longbridge.com/en/news/284835152.md)
*2026-04-30T20:49:27.000Z*
> Emergent BioSolutions shares are trading higher after the company reported better-than-expected Q1 financial results.

### [Emergent BioSolutions Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/284833924.md)
*2026-04-30T20:31:23.000Z*
> Gaithersburg-based Emergent BioSolutions Inc. (NYSE: EBS) announced its financial performance for the first quarter endi

### [Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox | EBS Stock News](https://longbridge.com/en/news/284763135.md)
*2026-04-30T03:55:35.000Z*
> Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (S